• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • TIP FAKÜLTESİ
  • Makale
  • Web of Science İndeksli Yayınlar
  • View Item
  •   DSpace Home
  • TIP FAKÜLTESİ
  • Makale
  • Web of Science İndeksli Yayınlar
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia

Thumbnail
View/Open
The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia.pdf (787.0Kb)
Date
2019
Author
Ghasemi, Mehdi and Okay, Mufide and Turk, Seyhan and Naeemaee, Ronak and Guver, Ebru and Malkan, Umit Y. and Aksu, Salih and Sayinalp, Nilgun and Haznedaroglu, Ibrahim C.
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
Introduction: Bone marrow renin-angiotensin system(RAS) modulates acute myeloid leukaemia(AML).The aim of this study is to clarify the relationships between RAS and AML, and to show the effect of losartan and doxorubicin treatment in AML cell lines. Methods: AML cell lines including CESS, HL-60, MO-1, P31/FUJ, GDM-1 and KASUMI-3 were used as models in this study. Results: After treating the six AML cell lines with a combination of losartan and doxorubicin, they were divided into two groups based on their behaviour: one became more sensitive to drug treatment (Group A) and the other had no change observed in behaviour after drug treatment (Group B). In silico analyses showed that Group A is involved in cellular apoptosis, while Group B is involved in tumour angiogenesis further supporting the in vitro results. Conclusion: The combined treatment of the AML cell lines with losartan and doxorubicin resulted in an increase in sensitivity of some of the cell lines. Those leukaemic cells are modulated via the induction of apoptosis, whereas the other cells resistant to the drug treatment are closely related to tumour angiogenesis indicating that RAS-AT1R seems to be differently expressed in different leukaemic blast cells and tumour microenvironments. Pharmaco-biological actions of RAS inhibitors may be different in distinct leukaemic cells based on the pathological behaviour of AML genomic subtypes.
URI
http://hdl.handle.net/20.500.12591/223
xmlui.mirage2.itemSummaryView.Collections
  • Web of Science İndeksli Yayınlar





Creative Commons License
DSpace@LokmanHekim by Lokman Hekim University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 



About HUAES
Open Access PolicyOpen Access InstructionGuidesSubcriptionsContact
sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV